Hypertensive nephropathy laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


{{CMG}}
{{CMG}}{{AE}}{{NN}}


==Laboratory Findings==
==Laboratory Findings==
* Blood tests
* Blood tests
** High levels of [[creatinine]], [[BUN]]
** High levels of [[creatinine]], [[BUN]]
** [[Anemia]]: Low [[Hb]] and [[hematocrit]]
** [[Anemia]]: low [[Hb]] and [[hematocrit]]
** [[Hyperlipidemia]]
** [[Hyperlipidemia]]
 
**Elevated serum levels of β2-microglobulin and transforming growth factor-β (TGF-β) have been recently found to predict the [[hypertensive nephropathy]]. <ref name="CaoHou2019">{{cite journal|last1=Cao|first1=Junjie |last2=Hou|first2=Rui |last3=Lu|first3=Jingqian |last4=Zhang|first4=Kongyan |last5=Zhao|first5=Cui |last6=Jiang|first6=Haisen |last7=Feng|first7=Yumei |last8=Wang|first8=Yiwei |title=The predictive value of β2‑MG and TGF‑β for elderly hypertensive nephropathy|journal=Experimental and Therapeutic Medicine|year=2019|issn=1792-0981|doi=10.3892/etm.2019.7278}}</ref>
* Urinary analysis
* Urinary analysis
** High protein levels
** High protein levels
*** May range from [[microalbuminuria]] (< 300 mg/ dl) to overt [[proteinuria]] (> 300 mg/ dl)
*** May range from [[microalbuminuria]] (< 300 mg/ dl) to overt [[proteinuria]] (> 300 mg/ dl)
*** Urinary albumin to creatinine ratio may be increased.
*** Urinary albumin to creatinine ratio may be increased.
**Presence of [[podocyte]] proteins in the urine precede [[proteinuria]], so it can be used as an early investigation. But, laboratory test for detecting [[podocytuia]] is not widely available. <ref name="SecciaCaroccia2017">{{cite journal|last1=Seccia|first1=Teresa M.|last2=Caroccia|first2=Brasilina|last3=Calò|first3=Lorenzo A.|title=Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms|journal=Journal of Hypertension|volume=35|issue=2|year=2017|pages=205–212|issn=0263-6352|doi=10.1097/HJH.0000000000001170}}</ref>
**Increased mRNA levels of [[podocin]] and [[nephrin]] in the urine is another early diagnostic test, which shows glomerular damage and developing [[hypertensive nephropathy]]. <ref name="SecciaCaroccia2017">{{cite journal|last1=Seccia|first1=Teresa M.|last2=Caroccia|first2=Brasilina|last3=Calò|first3=Lorenzo A.|title=Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms|journal=Journal of Hypertension|volume=35|issue=2|year=2017|pages=205–212|issn=0263-6352|doi=10.1097/HJH.0000000000001170}}</ref>


==References==
==References==

Revision as of 11:30, 14 June 2020

Hypertensive nephropathy Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Differentiating Hypertensive Nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Abdominal X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertensive nephropathy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypertensive nephropathy laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertensive nephropathy laboratory findings

CDC on Hypertensive nephropathy laboratory findings

Hypertensive nephropathy laboratory findings in the news

Blogs on Hypertensive nephropathy laboratory findings

Directions to Hospitals Treating Hypertensive nephropathy

Risk calculators and risk factors for Hypertensive nephropathy laboratory findings

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Laboratory Findings


References

  1. Cao, Junjie; Hou, Rui; Lu, Jingqian; Zhang, Kongyan; Zhao, Cui; Jiang, Haisen; Feng, Yumei; Wang, Yiwei (2019). "The predictive value of β2‑MG and TGF‑β for elderly hypertensive nephropathy". Experimental and Therapeutic Medicine. doi:10.3892/etm.2019.7278. ISSN 1792-0981.
  2. 2.0 2.1 Seccia, Teresa M.; Caroccia, Brasilina; Calò, Lorenzo A. (2017). "Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms". Journal of Hypertension. 35 (2): 205–212. doi:10.1097/HJH.0000000000001170. ISSN 0263-6352.

Template:WH Template:WS